Document is current
Any future updates will be listed below
-
Authors
Fry, Michelle Y
Navarro, Paula P
Hakim, Pusparanee https://orcid.org/0000-0002-9018-8179
Ananda, Virly Y
Qin, Xingping https://orcid.org/0000-0003-3263-0843
Landoni, Juan C https://orcid.org/0000-0002-0318-6707
Rath, Sneha
Inde, Zintis https://orcid.org/0000-0001-5564-1698
Lugo, Camila Makhlouta https://orcid.org/0000-0003-4655-8096
Luce, Bridget E
Ge, Yifan https://orcid.org/0000-0001-9135-9569
McDonald, Julie L https://orcid.org/0000-0002-3715-9619
Ali, Ilzat
Ha, Leillani L
Kleinstiver, Benjamin P
Chan, David C https://orcid.org/0000-0002-0191-2154
Sarosiek, Kristopher A
Chao, Luke H https://orcid.org/0000-0002-4849-4148
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_188112,P400PB_199252)
HHS | National Institutes of Health (F32AG077861)
HHS | National Institutes of Health (R35GM142553)
HHS | National Institutes of Health (R01DK125263,R37CA248565)
Howard Goodman Fellowship
Charles H. Hood Foundation
Alex’s Lemonade Stand Foundation for Childhood Cancer
Jane Coffin Childs Memorial Fund for Medical Research
- License Information
-
More Information
Article History
Received: 14 January 2023
Revised: 15 December 2023
Accepted: 22 December 2023
First Online: 15 January 2024
Disclosure and competing interests statement
: BPK is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. He is a consultant for EcoR1 capital and is an advisor to Acrigen Biosciences, Life Edit Therapeutics, and Prime Medicine. LHC is an advisor for Stealth Biotherapeutics. The remaining authors declare that there are no competing financial interests.
